During the last three months, 11 analysts shared their evaluations of 10x Genomics (NASDAQ:TXG), revealing diverse outlooks from bullish to bearish.
The following table encapsulates their recent ratings, offering a glimpse into the evolving sentiments over the past 30 days and comparing them to the preceding months.
| Bullish | Somewhat Bullish | Indifferent | Somewhat Bearish | Bearish | |
|---|---|---|---|---|---|
| Total Ratings | 3 | 2 | 5 | 0 | 1 |
| Last 30D | 0 | 1 | 1 | 0 | 0 |
| 1M Ago | 3 | 0 | 2 | 0 | 0 |
| 2M Ago | 0 | 1 | 1 | 0 | 1 |
| 3M Ago | 0 | 0 | 1 | 0 | 0 |
Analysts have recently evaluated 10x Genomics and provided 12-month price targets. The average target is $26.0, accompanied by a high estimate of $46.00 and a low estimate of $16.00. A 35.0% drop is evident in the current average compared to the previous average price target of $40.00.
Interpreting Analyst Ratings: A Closer Look
The analysis of recent analyst actions sheds light...
Login or create a forever free account to read this news
Sign up/Log in